SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
Crossref DOI link: https://doi.org/10.1007/s13300-022-01281-5
Published Online: 2022-06-15
Published Print: 2022-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Escalada, Javier http://orcid.org/0000-0001-5877-9465
Funding for this research was provided by:
AstraZeneca EspaƱa
Text and Data Mining valid from 2022-06-15
Version of Record valid from 2022-06-15
Article History
Received: 21 April 2022
Accepted: 13 May 2022
First Online: 15 June 2022